Welcome to our dedicated page for Healthcare Triangle news (Ticker: HCTI), a resource for investors and traders seeking the latest updates and insights on Healthcare Triangle stock.
Healthcare Triangle, Inc. reports developments in healthcare information technology, digital health platforms, cloud enablement, managed services, and data analytics for healthcare and life sciences organizations. Company news includes product and customer updates involving hospital information management, interoperability, telehealth, AI-powered clinical and operational automation, and customer-engagement tools.
Recurring HCTI updates also cover subsidiary activity at QuantumNexis, international expansion across Africa, the Middle East, and related healthcare markets, partnership and joint-venture activity, and capital-structure actions such as share repurchase authorization and reverse stock split disclosures.
Healthcare Triangle (HCTI) approved a stock dividend of a minority interest in Teyame AI Holdings common shares for existing HCTI shareholders, tied to a planned direct listing of Teyame AI Holdings on NASDAQ.
HCTI signed a Separation Agreement with its subsidiary Teyame AI Holdings that governs the separation, including allocation of assets and liabilities and transition services. Teyame AI Holdings owns HCTI’s recently acquired AI-powered customer experience businesses, Teyame 360 S.L. and Datono Mediación S.L. Completion of the direct listing depends on SEC review of a Teyame AI Holdings registration statement and NASDAQ approval of the listing. The stock dividend will be distributed to HCTI common shareholders of record on a future record date, which will be set after NASDAQ approves the direct listing.
Healthcare Triangle (Nasdaq: HCTI) reported Q2 2026 revenue of $9.19 million, a 158% year-over-year increase, with gross profit rising 322% to $2.07 million. Gross margin expanded to 22.5% from 13.8%, driven largely by its AI-powered customer engagement platform.
The AI platform contributed $6.31 million in Q2 revenue, about 69% of the total, and generated $1.64 million in segment gross profit at roughly 26% margin. For the first half of 2026, revenue reached $19.05 million and gross profit $4.46 million, up 162% and 444% year over year, respectively, with gross margin at 23.4%. Stockholders' equity increased to $49.1 million as of June 30, 2026, from $9.9 million at year-end 2025, reflecting a stronger balance sheet.
Healthcare Triangle (Nasdaq: HCTI) reported that subsidiary Teyame has, by June 2026, generated from a major Spanish health insurance client the same level of revenue it recorded from that client during all of 2025. The company projects this client could deliver €2 million in annual revenue for Teyame.
Teyame manages the client's omnichannel customer acquisition through AI-driven engagement and direct account management. According to Healthcare Triangle, these results highlight growth across its subsidiaries and support the strategic rationale for acquiring Teyame 360 SL and Datono Mediacion SL, the Spain-based entities behind Teyame's AI-powered customer experience platform.
Healthcare Triangle (Nasdaq: HCTI) signed a non-binding LOI to acquire a 51% equity stake in Melbourne-based CosmoAesthetics (CosmoInnovations) for a proposed US $23.5 million, payable in cash, equity and performance-linked milestones over three years.
According to Healthcare Triangle, the deal would shift its model from healthcare IT services toward a product-led innovation platform combining its AI and digital infrastructure with CosmoInnovations' MedTech, BeautyTech and consumer-health portfolio. CosmoInnovations contributes more than 25 proprietary technologies, 27 granted patents and 61 pending patent applications across skincare, light therapy, respiratory wellness, oral health, pain management, transdermal delivery and home-based care. CosmoInnovations’ management targets over US $50 million in cumulative revenue in the first three years post-acquisition, with an estimated US $33 million annualized run-rate by Year 3, though there is no assurance these targets will be achieved. Healthcare Triangle plans immediate independent IP and financial due diligence, and notes FDA establishment registration for a key LED technology manufacturer does not equal FDA clearance or approval.
Healthcare Triangle (Nasdaq: HCTI) completed the issuance of an aggregate 12,546,540 common shares on July 24, 2026 tied to two previously shareholder-approved legacy M&A transactions: the Teyame AI LLC acquisition and a Share Exchange Agreement with SecureKloud Technologies.
According to Healthcare Triangle, these issuances increased total common shares outstanding to 14,644,322 as of July 28, 2026. The larger float raised the company’s estimated Market Value of Listed Securities to about $23,870,244, based on a $1.63 closing share price, supporting its position relative to Nasdaq’s new $5 million minimum MVLS continued listing standard. The company noted that this is not a formal confirmation of compliance by Nasdaq, which makes its own determinations.
Healthcare Triangle (NASDAQ: HCTI) has created a wholly owned, AI-led healthcare technology services subsidiary, Purpose Health, and appointed veteran health tech executive Sumit Ganguli as its Chairman and CEO. Purpose Health will target U.S. and international providers, payors, life sciences and med‑tech clients with AI infrastructure, agentic AI and managed IT services.
According to Healthcare Triangle, Purpose Health is designed to emphasize capital‑efficient, high‑margin, multi‑year recurring revenue models, including strategic joint ventures. Ganguli previously helped scale a healthcare and technology company 18-fold to about $175 million in revenue and directed multi‑year client engagements valued between $25 million and $300 million.
Healthcare Triangle (Nasdaq:HCTI) completed a private placement of 15% original issue discount senior convertible promissory notes with an aggregate principal of $4.235 million, generating approximately $3.6 million in gross proceeds.
The notes mature on December 12, 2026 and become convertible six months after issuance at 85% of VWAP for the prior three trading days. Healthcare Triangle plans to use net proceeds to repay certain prior debt, pursue potential strategic acquisitions, and for general working capital. The securities are unregistered and rely on applicable exemptions under U.S. securities laws.
Healthcare Triangle (Nasdaq:HCTI) closed a private placement of 15% original issue discount senior convertible promissory notes with an aggregate principal of $4.235 million, generating approximately $3.6 million in gross proceeds.
The notes mature on December 12, 2026 and are convertible after six months at 85% of VWAP. Proceeds are earmarked for debt repayment, strategic acquisitions, and working capital.
Healthcare Triangle (Nasdaq:HCTI) reported strong Q1 2026 results, driven by its January acquisition of Teyame 360 and Datono.
Revenue rose 166% year-over-year to $9.9M, while gross profit increased 627% to $2.4M and gross margin expanded from 9% to 24%.
The new Customer Engagement Services segment, created from the acquired businesses, delivered $6.9M revenue (about 70% of total), $2.0M gross profit and roughly 29% segment margin, offsetting modest declines in legacy Software Services and Managed Services. Management expects further gross margin improvement as integration and cross-selling progress.
Healthcare Triangle (NASDAQ: HCTI) launched ZoraNex, an AI-driven digital self-care therapy platform developed by subsidiary QuantumNexis, targeting mild-to-moderate stress, anxiety, depression, and sleep issues. ZoraNex will be available on Apple App Store and Google Play before end of Q2 2026 and targets a global mental health market valued at $450B (2024).
The platform combines evidence-based psychotherapies with Eastern mind-body practices, avatar-led sessions, wearable integration, and a hybrid DTC and enterprise go-to-market focused on Southeast Asia (Malaysia first).